Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.15 USD | +2.01% | +24.49% | +82.27% |
Financials (USD)
Sales 2024 * | 71.56M | Sales 2025 * | 277M | Capitalization | 6.19B |
---|---|---|---|---|---|
Net income 2024 * | -437M | Net income 2025 * | -307M | EV / Sales 2024 * | 86.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 22.3 x |
P/E ratio 2024 * |
-12.3
x | P/E ratio 2025 * |
-17.6
x | Employees | 628 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 20.69% |
Latest transcript on ImmunityBio, Inc.
1 day | +2.01% | ||
1 week | +24.49% | ||
Current month | +14.52% | ||
1 month | +62.81% | ||
3 months | +121.01% | ||
6 months | +144.00% | ||
Current year | +82.27% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Adcock
CEO | Chief Executive Officer | 55 | 20-09-30 |
Founder | 71 | 14-11-30 | |
David Sachs
DFI | Director of Finance/CFO | 46 | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 71 | 14-11-30 | |
Cheryl L. Cohen
BRD | Director/Board Member | 58 | 19-05-31 |
Wesley Clark
BRD | Director/Board Member | 78 | 21-02-23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 9.15 | +2.01% | 14,704,253 |
24-05-02 | 8.97 | +5.04% | 9,810,042 |
24-05-01 | 8.54 | +6.88% | 12,801,089 |
24-04-30 | 7.99 | -11.12% | 15,004,108 |
24-04-29 | 8.99 | +22.31% | 66,104,815 |
Delayed Quote Nasdaq, May 03, 2024 at 04:15 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+82.27% | 6.19B | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- IBRX Stock